New research released today reveals that despite one
million New Zealanders being eligible to treat their
COVID-19 infection with antiviral medication*, over half
(54%) know very little about the treatments.
The
online study of more than 1,500 Kiwis, sponsored by Pfizer,
was undertaken in partnership with New Zealand research firm
Talbot Mills to understand New Zealanders’ awareness of
antivirals.
Pfizer New Zealand Medical Director,
Krishan Thiru said it is concerning that so many vulnerable
Kiwis are largely unknowing of this potentially lifesaving
treatment.
“The findings show that those most at
risk are lacking overall understanding of antiviral
treatments, their benefits and how to access them. Our
concern is that this may not improve over summer unless we
work together to ensure those who need it the most are not
left behind.”
In the EPIC-HR trial, it was found
that Pfizer’s antiviral treatment PAXLOVID reduced the
risk of hospital admission or dying from COVID-19 by up to
86%, compared to placebo, in non-hospitalised, high-risk
adult and unvaccinated patients treated within five days of
symptom onset. [i]
When
explained how PAXLOVID works and the potential benefits of
the treatment, nearly two thirds (62%) of the general public
aware of antivirals said having access to the medicine would
make them less fearful of catching the virus. For those who
are highest risk of death and hospitalisations from
COVID-19, three in five (61%) said it made them less
fearful.
The eligibility criteria for antivirals is
aimed at New Zealanders who have the highest risk of death
and hospitalisations from COVID-19. Research released last
month by the Public Health Agency, found Māori and
Pasifika, those with underlying health conditions, and older
Kiwis are among those who have a much higher risk of dying
from the virus.
The research found that over half
(54%) of people who identified as Māori and Pasifika and
were aged over 50 said their knowledge of antivirals was
poor.
Thiru said it was important that
disproportionately affected communities talk about the
COVID-19 treatment options available so that their whānau
are protected and feel empowered to learn more and seek
advice from a health professional.
“While
vaccination remains the most effective way to help prevent
COVID-19, antiviral treatments provide a strong second line
of defence for those most at risk,” Thiru
said.
“Eligible New Zealanders need to act fast
after testing positive for COVID-19, calling their doctor or
pharmacist straight away.”
“PAXLOVID is fully
funded and now available for eligible New Zealanders at over
400 pharmacy locations nationwide, with free delivery
offered to patients’ homes if required. This means more
Kiwis will be able to access the medication either through
their healthcare professional or from a pharmacy, helping to
reduce the strain on our health system,” he
said.
People who think they may be eligible for
PAXLOVID are encouraged to talk to their pharmacist or
general practitioner (GP) about their eligibility for
antiviral medication. Eligibility will depend on several
factors, including age, ethnicity, other health conditions
and vaccination status.
Speak to your pharmacist or GP
to check if PAXLOVID is right for you. For more details, check
out Pharmac’s access criteria here and visit: www.treatpositive.co.nz.
© Scoop Media



















Discussion about this post